American Journal of Clinical Dermatology American Journal of Clinical Dermatology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - November 27, 2023 Category: Dermatology Source Type: research

What ’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus
AbstractCutaneous T-cell lymphomas are a heterogenous group of lymphomas that cause various skin manifestations. Severe pruritus occurs frequently in cutaneous T-cell lymphoma and negatively impacts patients ’ quality of life. The pathophysiology of cutaneous T-cell lymphoma-associated itch is complex and involves various immune cells, inflammatory cytokines, and neuroimmune interactions. Treating cutaneous T-cell lymphoma pruritus can be challenging, and there have been few randomized controlled stud ies evaluating the use of antipruritic treatments in these patients. Systemic therapies targeting the disease have also b...
Source: American Journal of Clinical Dermatology - November 16, 2023 Category: Dermatology Source Type: research

Non-invasive Skin Imaging in Cutaneous Lymphomas
AbstractThe diagnosis of cutaneous lymphomas is challenging and requires skin tissue for histology and immunophenotyping using immunohistochemistry and molecular studies. In recent years, the role of non-invasive imaging techniques has been described as part of the clinical assessment of cutaneous lymphoma lesions. Imaging modalities such as dermoscopy, reflectance confocal microscopy (RCM), and high frequency ultrasound (HFUS) have been shown to be very valuable in raising the clinical suspicion for lymphomas of the skin, and in distinguishing cutaneous lymphomas from inflammatory dermatoses such as lupus, psoriasis, or e...
Source: American Journal of Clinical Dermatology - November 14, 2023 Category: Dermatology Source Type: research

Correction to: AtopyReg ®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - November 7, 2023 Category: Dermatology Source Type: research

Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives
AbstractHormonal and immunologic changes during pregnancy can contribute to the development of different dermatoses, the most common of which is atopic eruption of pregnancy (AEP). Of atopic dermatitis (AD) cases during pregnancy, 80% are new-onset presentations, while 20% represent recurrences or exacerbations of preexisting disease. Evidence on the effects of previous AD on fertility is limited. Different factors influence women ’s desire to conceive in this setting, and it has been hypothesized that barrier defects and systemic inflammation could contribute to biologic infertility, although more data are needed. Clini...
Source: American Journal of Clinical Dermatology - October 30, 2023 Category: Dermatology Source Type: research

Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
ConclusionA substantial (22.7%) number of guselkumab-treated patients in the VOYAGE 1 clinical trial maintained complete skin clearance for a consecutive period of ≥ 156 weeks. Factors associated with this outcome may suggest clinical benefits of holistic treatment approaches.Trial RegistrationNCT02207231. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - October 7, 2023 Category: Dermatology Source Type: research

Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
ConclusionsTralokinumab provided clinically meaningful responses in patients with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 at week 16 and/or used rescue medication. Using multiple validated outcome measures of both efficacy and quality of life, alongside IGA scores, can better characterize tralokinumab treatment responses in patients with moderate-to-severe atopic dermatitis. [Video abstract available]Clinical Trial RegistrationNCT03131648 (ECZTRA 1); study start date: 30 May, 2017; primary completion date: 7 August, 2018; study completion date: 10 October, 2019. NCT03160885 (ECZTRA 2); study start ...
Source: American Journal of Clinical Dermatology - October 7, 2023 Category: Dermatology Source Type: research

AtopyReg ®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History
ConclusionsThis baseline data analysis deriving from AtopyReg® provides real-life evidence on patients with moderate-to-severe atopic dermatitis in Italy confirming the high burden of atopic dermatitis with a significant impact on patients ’ quality of life. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 19, 2023 Category: Dermatology Source Type: research

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments
AbstractChronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching. Patients with CPG experience a significant psychological burden and a notable impairment in their quality of life. Chronic prurigo of nodular type (CNPG; synonym: prurigo nodularis) represents the most common subtype of CPG. As CNPG is representative for all CPG subtypes, we refer in this review to both CNPG and CPG. We provide an overview of the clinical characteristics and assessment...
Source: American Journal of Clinical Dermatology - September 17, 2023 Category: Dermatology Source Type: research

Oral Lichen Planus: An Update on Diagnosis and Management
AbstractOral lichen planus (OLP) is a chronic inflammatory disease whose pathogenesis involves a T-cell mediated, epithelium-directed inflammation in response to unknown antigen(s). The disease evolves by intermittent flares and displays polymorphous clinical features (reticular, erosive, atrophic, plaque, papular, bullous, etc.). When present, symptoms vary depending on the clinical form and range from discomfort to severe pain. Topical superpotent corticosteroids constitute the first-line treatment of symptomatic flares, whereas a wide range of second/third-line treatments are available among topical calcineurin inhibito...
Source: American Journal of Clinical Dermatology - September 15, 2023 Category: Dermatology Source Type: research

Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
AbstractAtopic dermatitis (AD) is a chronic inflammatory disease requiring efficacious and safe long-term therapy. Several new systemic treatments have recently been approved for use in patients with moderate to severe AD. However, head-to-head comparisons have not been conducted for all the currently available treatments for AD. Multiple network meta-analyses have compared efficacy of these different therapies during the initial 16-week treatment period, but not beyond week 16. Therefore, understanding the differences in key trial design and statistical methods is essential for evaluating long-term efficacy, making cross-...
Source: American Journal of Clinical Dermatology - September 11, 2023 Category: Dermatology Source Type: research

Correction to: Authors ’ Reply to Chen and Chen: Comment on: “Isotretinoin Exposure and Risk of Infammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis”
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 9, 2023 Category: Dermatology Source Type: research

Tralokinumab Efficacy Over 1  Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
ConclusionsTralokinumab treatment provides progressive and sustained improvement over 1 year in the extent and severity of AD in patients with moderate-to-severe AD.Clinical Trial RegistrationNCT03131648 (ECZTRA 1); study start date: 30 May 2017; primary completion date: 7 August 2018; study completion date: 10 October 2019. NCT03160885 (ECZTRA 2); study start date: 12 June 2017; primary completion date: 4 September 2019; study completion date: 14 August 2019.Infographic (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 8, 2023 Category: Dermatology Source Type: research